AMRN
USDAmarin Corporation plc
实时价格
价格图表
关键指标
市场指标
开盘价
$15.670
最高价
$15.745
最低价
$15.110
成交量
0.06M
公司基本面
市值
326.7M
所属行业
Drug Manufacturers - General
国家/地区
Ireland
交易统计
平均成交量
0.10M
交易所
NCM
货币
USD
52周价格范围
AI分析报告
最后更新: 2025年11月5日AMRN Analysis: Navigating Short-Term Volatility in Amarin Corporation Shares
Key Takeaways
- Recent technical indicators show bullish momentum but conflicting signals
- Q3 2025 results triggered sharp price drop, reflecting operational uncertainty
- Stock trades at historical discount to 52-week highs but risks remain
- Fundamental risks outweigh short-term value opportunities
Recent News Impact
Positive Developments
- Scientific Validation (Nov 3, 2025) New analyses presented at AHA Scientific Sessions reinforce Vascepa’s clinical data consistency and mechanism of action.
- FDA Labeling Support (Oct 27, 2025) Company publicly aligned with FDA’s fenofibrate labeling revision, potentially strengthening Vascepa’s competitive differentiation.
Mixed Earnings Release (Oct 29, 2025)
Q3 results highlighted international expansion progress but triggered a 10% single-day crash (from $18.50 to $16.70), suggesting market skepticism about execution risks in the new commercialization model.
相关新闻
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new
Amarin Reports Third Quarter 2025 Financial Results
Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand,
Amarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the following statement
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian
AI预测Beta
AI建议
更新于: 2025年11月10日 13:07
58.4% 置信度
风险与交易
入场点
$15.36
止盈点
$15.93
止损点
$14.06
关键因素
相关股票
保持更新
设置价格提醒，获取AI分析更新和实时市场新闻。